World's largest population study combining blood biomarkers and genetics demonstrates Nightingale Health's risk prediction models outperform genetic risk prediction in chronic diseases
Press release, 15 June 2023 at 9:00 a.m. (EEST) Nightingale Health Plc (“Nightingale Health”), a technology company promoting preventative health with its proprietary health risk detection platform, has published a pre-print showcasing the accuracy and performance of its blood biomarker-based risk prediction models on a scale that has not been done before. The now-announced population study includes three national biobanks totaling half a million blood samples from Estonia, Finland, and the United Kingdom. In